LA MESA, Calif., April 12, 2005 (PRIMEZONE) -- Nicodrops, Inc. (Pink Sheets:NCDP), developer of the drug-free, non-nicotine smoking alternative, herbal dietary supplement, LOZENGE(i), today announced a national advertising rollout to promote its product. The campaign is set to begin in late May/early June. The initial campaign will start with nationally known National Enquirer magazine.
"Now that we have solid distribution in place coast to coast we are ready to kickoff an aggressive marketing and advertising campaign to build product and brand name awareness," said Christopher Calpito, president and CEO of Nicodrops, Inc. "We are very confident we can ramp up revenues by adding distribution channels in combination with a strong marketing plan."
Calpito said the company plans on targeting its marketing in late May and will continue after that with follow up ads for Back to School as well as a year-end New Year's Resolution campaign. All three campaigns will include a toll-free number to order the product. The ad will state "available at Walgreens" which carries Nicodrops in all 4,700 plus stores.
"Our goal with this marketing campaign is twofold - to sell Nicodrops and to help heighten awareness of our drug-free, non-nicotine smoking alternative product," said Joel Appel, Director of Marketing and Sales for Nicodrops. "We will ramp up the number of publications as we continue with our Back to School marketing program and year-end program. The campaign is geared toward increasing market share."
About Nicodrops:
Nicodrops Inc., La Mesa, CA, developed a drug free, non-nicotine product which helps reduce the stress associated with not smoking, using all natural herbs.(i) For more information go to www.nicodrops.com or call 1-866-844-5383.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. The words "believe," "expect," "anticipate", and "project", and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Such statements may include, but not be limited to, projections of revenues, income or loss, expenses, plans, and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future results could differ materially from those described in forward-looking statements.
(i) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseases.